Table 1.
Level of the health care system | |||||
---|---|---|---|---|---|
Supply side | Demand side | ||||
Access component | Action | International | National (or State or Province) | District health service | Individual, household or community |
SELECTION | (A1) Developing and implementing a medicine selection process | X | X | X | |
(A2) Promoting information and education activities for staff and users on the selection process | X | X | |||
AVAILABILITY | (A3) Regulating psychotropic medicine availability | * | X | ||
(A4) Implementing a reliable health and supply system | * | X | |||
(A5) Ensuring quality of psychotropic medicines | * | X | |||
(A6) Developing a community-based system of mental health care | X | X | X | ||
AFFORDABILITY | (A7) Developing policies on medicine affordability | X | |||
(A8) Developing pricing policies and fostering of a sustainable financing system | X | ||||
APPROPRIATE USE | (A9) Developing and implementing evidence-based guidelines | X | X | X | † |
(A10) Monitoring the use of psychotropic medicines | X | X | ‡ | ||
(A11) Promoting training initiatives for staff and users on critical appraisal of scientific evidence and appropriate use of psychotropic medicines | X | X | X |
Guidance is provided by international organisations, such as the World Health Organization.
According to guideline production methodology, representatives of patients, families and the wider society should be included in guideline development process.
As part of monitoring activities, research projects should be implemented with active participation of service users.